Alpertine (, ; developmental code name WIN-31665) is a drug of the pertine group described as an antipsychotic, neuroleptic, and tranqulizer which was never marketed.
Structurally, it is a substituted tryptamine and a piperazinylethylindole. The drug is closely structurally related to other "pertines" including milipertine, oxypertine, and solypertine, which are also tryptamines and piperazinylethylindoles.
The related drug oxypertine shows high affinity for the serotonin 5-HT<sub>2</sub> and dopamine D<sub>2</sub> receptors (K<sub>i</sub> = 8.6nM and 30nM, respectively) and is also known to act as a catecholamine depleting agent. Oxypertine, milipertine, and solypertine all antagonize the behavioral effects of tryptamine, a serotonin receptor agonist, and apomorphine, a dopamine receptor agonist, in animals. Conversely however, alpertine was not effective, at least at doses of up to 10mg/kg. ortho-Methoxyphenylpiperazine (oMeOPP) has been said to be a metabolite of the related drugs milipertine and oxypertine.
Alpertine was first described in the scientific literature by 1971.